DES1: A Key Driver of Lipotoxicity in Metabolic Disease
Year: 2020
Type: article
Abstract: Ceramides have emerged as important regulators of tissue metabolism that play essential roles in cardiometabolic disease. They are potent biomarkers of diabetes and heart disease and are now being measured clinically as predictors of major adverse cardiac events. Moreover, studies in rodents reveal that inhibitors of ceramide synthesis prevent or reverse the pathogenic features of type 2 diabetes, nonalcoholic fatty liver disease, atherosclerosis, and cardiomyopathy. Herein the authors discuss inhibition of dihydroceramide desaturase-1, the final enzyme in the ceramide biosynthesis pathway, as a potential therapeutic approach to lower ceramides and combat cardiometabolic disease.
Source: DNA and Cell Biology
Institution: University of Utah
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Awards: G311281104, G3813662056
OpenAlex ID: W3011471913
